MMSL 2023, 92(4):325-332 | DOI: 10.31482/mmsl.2022.051

BIOCHEMICAL AND HISTOLOGICAL CHANGES IN REPRODUCTIVE ORGANS OF EXPERIMENTAL RATS AFTER DIENOGEST THERAPYOriginal article

Hadeel Anwer Alsarraje ORCID...*, Liqaa Khalel Alhyali, Ehsan Hassan Aldabbagh ORCID...
College of Medicine, University of Mosul, Mosul, Iraq

The precise method of action of dienogest on the production and development of endometriosis lesions is unknown, and its controversial effect on endometrial thickness has been under investigation. In the following study the Dienogest's effects on the target animal's histology of female reproductive organs, including the tissues from the Fallopian tubes, ovaries, and uterus, as well as the impact of drug administration on the liver's enzymes and the drug's effects on triglycerides, body weight, and HbA1c, have all been studied. The findings of the following experiment indicated that there was no significant elevation of liver enzymes. The little to no elevation of the liver enzymes indicated that the drug did not induce stress on the hepatic cells and according to the subsequent experiment it is safe for clinical use. Moreover, after 10, 20, and 30 days of blood administration, the level of blood TG significantly decreased, and after 30 days of intake, the level of blood sugar significantly decreased. However, there were no appreciable changes after 10 and 20 days. After 30 days of treatment, the rats' weight also showed a very minor drop. In addition to it, the results of histological changes in the tissue in the following study represented that there were evident changes in the tissues which comprised of decline in blood circulation, fibrosis in tissues, and degeneration of follicles.

Keywords: Dienogest; contraceptive; progesterone; liver; metabolic effects

Received: July 29, 2022; Revised: July 29, 2022; Accepted: November 22, 2022; Prepublished online: February 2, 2023; Published: December 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Anwer Alsarraje, H., Khalel Alhyali, L., & Aldabbagh, E.H. (2023). BIOCHEMICAL AND HISTOLOGICAL CHANGES IN REPRODUCTIVE ORGANS OF EXPERIMENTAL RATS AFTER DIENOGEST THERAPY. MMSL92(4), 325-332. doi: 10.31482/mmsl.2022.051
Download citation

References

  1. Liang B, Wu L, Xu H, et al. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reproductive Biology and Endocrinology. 2018 Dec;16:1-3. https://doi.org/10.1186/s12958-018-0347-9. Go to original source... Go to PubMed...
  2. Lee A, Sugiura Y, Cho IH, et al. In Vivo Hypoglycemic Effects, Potential Mechanisms and LC-MS/MS Analysis of Dendropanax trifidus Sap Extract. Nutrients. 2021 Nov 30;13(12):4332. https://doi.org/10.3390/nu13124332. Go to original source... Go to PubMed...
  3. Barra F, Scala C, Leone Roberti Maggiore U, et al. Long-term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis. Journal of clinical medicine. 2020 Jan 6;9(1):154. https://doi.org/10.3390/jcm9010154. Go to original source... Go to PubMed...
  4. Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Archives of gynecology and obstetrics. 2012 Jan;285:167-173. https://doi.org/10.1007/s00404-011-1941-7 Go to original source... Go to PubMed...
  5. Piacenti I, Viscardi MF, Masciullo L, et al. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice?. Gynecological Endocrinology. 2021 May 4;37(5):471-475. https://doi.org/10.1080/09513590.2021.1892632. Go to original source... Go to PubMed...
  6. Rukhliada NN, Krylov KY. Visanne and Qlaira in therapy of metrorrhagic adenomyosis, leading to excessive menstrual blood loss and anemia. Global Reproduction. 2019(3):12-16.
  7. Göhring J, Drewes M, Kalder M, et al. Germany endometriosis pattern changes; prevalence and therapy over 2010 and 2019 years: a retrospective cross-sectional study. International Journal of Fertility & Sterility. 2022 Apr;16(2):85. https://doi.org/10.22074/IJFS.2021.528397.1113. Go to original source... Go to PubMed...
  8. Lorenz C, Krüger A, Schöning V, et al. The progestin norethisterone affects thyroid hormone-dependent metamorphosis of Xenopus laevis tadpoles at environmentally relevant concentrations. Ecotoxicology and Environmental Safety. 2018 Apr 15;150:86-95. https://doi.org/10.1016/j.ecoenv.2017.12.022. Go to original source... Go to PubMed...
  9. Russu MC. Potential Therapeutic Options and Perspectives for Alleviation of Endometrial Estrogen Dominance and Progesterone Resistance in Endometriosis. Endometriosis: Recent Advances, New Perspectives and Treatments. 2022 Jun 28:35.
  10. Oettel M, Zentel HJ, Nickisch K. A progestin isn'ta progestin: dienogest for endometriosis as a blueprint for future research-Review as a contribution for discussion. Hormone Molecular Biology and Clinical Investigation. 2021 Jun 1;42(2):133-142. https://doi.org/10.1515/hmbci-2020-0013. Go to original source... Go to PubMed...
  11. Lee JH, Song JY, Yi KW, et al. Effectiveness of dienogest for treatment of recurrent endometriosis: multicenter data. Reproductive Sciences. 2018 Oct;25(10):1515-1522. https://doi.org/10.1177/1933719118779733. Go to original source... Go to PubMed...
  12. Kim YS, Kim YJ, Kim MJ, et al. Novel medicine for endometriosis and its therapeutic effect in a mouse model. Biomedicines. 2020 Dec 16;8(12):619. https://doi.org/10.3390/biomedicines8120619. Go to original source... Go to PubMed...
  13. Schmid S, Willi RA, Salgueiro-González N, et al. Effects of new generation progestins, including as mixtures and in combination with other classes of steroid hormones, on zebrafish early life stages. Science of The Total Environment. 2020 Mar 20;709:136262. https://doi.org/10.1016/j.scitotenv.2019.136262. Go to original source... Go to PubMed...
  14. Abdulqader SW, Faisal IM, Saeed MG, et al. Fluvoxamine Suppressed Oxidative Stress associated with Tissue Erosion. Research Journal of Pharmacy and Technology. 2022 Feb 1;15(2):819-824. https://doi.org/10.5958/0974-360X. Go to original source...
  15. Abdulqader SW, Faisal IM, Saeed MG, et al. Fluvoxamine Provide a Gastro-Protection Against Vitiated Insult. Indian Journal of Forensic Medicine & Toxicology. 2022 Jan 1;16(1):1047. https://doi.org/10.37506/ijfmt.v16i1.17633. Go to original source...
  16. Barberino RS, Silva RL, Palheta Junior RC, et al. Protective Effects of Antioxidants on Cyclophosphamide-Induced Ovarian Toxicity. Biopreservation and Biobanking. 2022 Jun 13. https://doi.org/10.1089/bio.2021.0159. Go to original source... Go to PubMed...
  17. Almukhtar HM, Faisal IM, Merkhan MM. Short-term treatment with Atorvastatin selectively decreases Lymphocyte count. Research Journal of Pharmacy and Technology. 2022 Feb 1;15(2):689-694. https://doi.org/10.52711/0974-360X.2022.00114. Go to original source...
  18. Almukhtar HM, Faisal IM, Merkhan MM. Acute effect of atorvastatin in comparison with rosuvastatin on glucose homeostasis in hypercholesteremic patients. Pharmacology. 2021;25:25-34.
  19. Althanoon Z, Faisal IM, Ahmad AA, et al. Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Systematic Reviews in Pharmacy. 2020 Jul 1;11(7):167-171.
  20. Chou CH, Chen MJ. The effect of steroid hormones on ovarian follicle development. Vitamins and hormones. 2018 Jan 1;107:155-175. https://doi.org/10.1016/bs.vh.2018.01.013. Go to original source... Go to PubMed...
  21. Muraoka A, Osuka S, Yabuki A, et al. Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial. Reproductive Biology and Endocrinology. 2021 Dec;19(1):1-9. https://doi.org/10.1186/s12958-021-00866-2. Go to original source... Go to PubMed...
  22. Dobrokhotova JE, Kalimatova DM, Ilyina IY, et al. Study of dienogest clinical efficacy in the treatment of adenomyosis. Journal of Endometriosis and Pelvic Pain Disorders. 2021 Jun;13(2):136-141. https://doi.org/10.1177/2284026521993699. Go to original source...
  23. Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis. InSeminars in reproductive medicine 2020 May;38(02/03):151-156). Thieme Medical Publishers, Inc. https://doi.org/10.1055/s-0040-1719016. Go to original source... Go to PubMed...
  24. Bastianelli C, Farris M, Bruni V, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 4. Effects on uterine and cervical epithelia. Expert Review of Clinical Pharmacology. 2020 Feb 1;13(2):163-182. https://doi.org/10.1080/17512433.2017.1271708. Go to original source... Go to PubMed...
  25. Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Research. 2019;8. https://doi.org/10.12688/f1000research.14817.1. Go to original source... Go to PubMed...
  26. Benesic A, Jalal K, Gerbes AL. Drug-drug combinations can enhance toxicity as shown by monocyte-derived hepatocyte-like cells from patients with idiosyncratic drug-induced liver injury. Toxicological Sciences. 2019 Oct 1;171(2):296-302. https://doi.org/10.1093/toxsci/kfz156. Go to original source... Go to PubMed...
  27. Peinado AB, Alfaro-Magallanes VM, Romero-Parra N, et al. Methodological approach of the iron and muscular damage: female metabolism and menstrual cycle during exercise project (IronFEMME Study). International Journal of Environmental Research and Public Health. 2021 Jan;18(2):735. https://doi.org/10.3390/ijerph18020735. Go to original source... Go to PubMed...